TD Cowen lowered the firm’s price target on Elevance Health to $555 from $585 and keeps an Outperform rating on the shares. The firm updated its model with immaterial changes to 2023-35 EPS. In general higher interest income assumptions offset lost Medicaid enrollment in 2025 and anticipated slower MA enrollment growth in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELV:
- Elevance Health reports Medical membership totaled ~47.3M at Sept. 30
- Elevance Health raises FY23 adjusted EPS view to greater than $33.00 per share
- Elevance Health reports Q3 adjusted EPS $8.99, consensus $8.44
- CVS biggest beneficiary of Medicare Advantage stars scores, says BofA
- Elevance Health, Inc. (ELV) Q3 Earnings Cheat Sheet